DUSSELDORF, Germany, Nov. 20, 2013 /PRNewswire/ -- ResMed (NYSE: RMD), an innovator and pioneer in developing products for the treatment of sleep-disordered breathing and respiratory conditions, has won preliminary injunctions in Germany against several patent infringing activities by Taiwanese medical device manufacturer APEX Medical Corp. (APEX) and Chinese medical device manufacturer BMC Medical Co., Ltd. (BMC). The initial orders, entered by the Munich District Court, prohibit APEX and BMC from selling or marketing certain products in Germany without a further court order. Those products are:
ResMed has also filed patent infringement lawsuits in Munich, Germany, seeking damages and permanent injunctions to stop infringement of ResMed patents by the products listed above, as well as the additional products below:
Earlier this year, ResMed pursued similar legal actions against APEX and BMC in the United States with the International Trade Commission (ITC). The U.S. government investigation started at ResMed's request against APEX resulted in an ITC consent decree against APEX stopping the importation and sale of infringing APEX products. Proceedings against BMC are ongoing.
"ResMed has a global business built on its investment in research and development, resulting in products that excel in performance, quality and comfort," said David Pendarvis, ResMed global general counsel and chief administrative officer. "We will continue to defend our investment in intellectual property and pursue all legal remedies to prevent infringement in any country where that infringement exists."
ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.
(Logo: http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)Contacts:For News Media For the Investor CommunityGretchen Griswold
Constance BienfaitDirector, Global Corporate Communications
Director, Investor RelationsO: 858-836-6789
|SOURCE ResMed Inc.|
Copyright©2012 PR Newswire.
All rights reserved